Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1833
Revised: May 21, 2024
Accepted: June 21, 2024
Published online: September 15, 2024
Processing time: 166 Days and 8 Hours
The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes, cardiovascular disease (CVD), and obesity. This diverse community of microorganisms controls a variety of physiological func
Core Tip: The gut microbiota plays a crucial role in the onset and progression of metabolic conditions like type 2 diabetes, cardiovascular disease, and obesity. This diverse microbial community regulates various physiological functions, including metabolism, inflammation, and immune response. Understanding these interactions has led to innovative therapeutic approaches, such as microbiome supplementation. Dietary changes significantly impact the composition and function of the gut microbiome, influencing metabolite production that directly impacts host well-being. Certain metabolites like butyrate and propionate exhibit protective effects against metabolic disorders, while trimethylamine is associated with cardiovascular risk. Researchers explore prebiotics, probiotics, synbiotics, and postbiotics as potential avenues to modulate the gut microbiome and enhance metabolic health. Despite therapeutic advancements and lifestyle modifications, the prevalence of metabolic syndrome continues to rise, underscoring the urgent need for novel treatments.
- Citation: Qureshi W, Dar MA, Rather MY. New therapy for metabolic syndrome: Gut microbiome supplementation. World J Diabetes 2024; 15(9): 1833-1836
- URL: https://www.wjgnet.com/1948-9358/full/v15/i9/1833.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i9.1833
The complex relationship between the gut microbiome and metabolic health has received a lot of attention in recent years, revolutionizing our understanding of the pathogenesis and potential treatment options for metabolic disorders like type 2 diabetes, cardiovascular disease (CVD), and obesity. The gut microbiota, a varied population of bacteria living in the intestines, orchestrates a wide range of physiological processes such as metabolism, inflammatory regulation, and im
The gut microbiome, comprising a diverse community of bacteria residing in the intestines, has emerged as a crucial player in the development and progression of metabolic disorders such as type 2 diabetes mellitus (T2DM), CVD, and obesity[1]. The gut microbiota, which contains billions of microorganisms, regulates a variety of physiological functions such as metabolism, inflammation, and immunological response. Understanding these intricate relationships has led to new paths for therapeutic approaches, with microbiome supplementation appearing as a promising option[2]. The gut microbiome is extremely sensitive to dietary composition, with research indicating that changing diets, such as animal-based vs plant-based diets can drastically alter the gut microbiota's composition and function. This, in turn, can alter the formation of metabolites that affect host physiology, such as SCFAs, bile acids, and other bioactive substances[3]. Certain metabolites produced by the gut microbiota, such as butyrate and propionate, have been proven in studies to protect against metabolic disorders such as type 2 diabetes and CVD. These metabolites promote colon health, increase insulin sensitivity, and regulate lipid metabolism. However, other metabolites, such as trimethylamine, can cause atherosclerosis, thrombosis, and CVD, emphasizing the intricate interplay between the gut microbiota and metabolic health[4]. To modify the gut microbiome and promote metabolic health, researchers are investigating the use of prebiotics, probiotics, synbiotics, and postbiotics. Prebiotics such as inulin, lactulose, and FOS preferentially enhance the development of beneficial bacteria such as Bifidobacterium and Lactobacillus, resulting in the synthesis of SCFAs and increased gut barrier integrity[5]. Despite advancements in conventional treatments and lifestyle modifications, the prevalence of metabolic syndrome continues to rise, underscoring the urgent need for innovative therapeutic strategies. Recent research has shed light on the pivotal role of the gut microbiota in metabolic health, offering new avenues for intervention[6]. A compelling study published in the World Journal of Diabetes presents evidence for the therapeutic potential of gut mi
The rapidly expanding field of study into the gut microbiome's impact in metabolic health has revealed new pathways for therapeutic intervention and personalized treatment options. Researchers discovered intriguing opportunities for mo
1. | Iatcu CO, Steen A, Covasa M. Gut Microbiota and Complications of Type-2 Diabetes. Nutrients. 2021;14. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 137] [Article Influence: 45.7] [Reference Citation Analysis (0)] |
2. | Ghosh TS, Shanahan F, O'Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol. 2022;19:565-584. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 110] [Cited by in F6Publishing: 214] [Article Influence: 107.0] [Reference Citation Analysis (0)] |
3. | Cronin P, Joyce SA, O'Toole PW, O'Connor EM. Dietary Fibre Modulates the Gut Microbiota. Nutrients. 2021;13. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 61] [Cited by in F6Publishing: 251] [Article Influence: 83.7] [Reference Citation Analysis (0)] |
4. | Mayorga-Ramos A, Barba-Ostria C, Simancas-Racines D, Guamán LP. Protective role of butyrate in obesity and diabetes: New insights. Front Nutr. 2022;9:1067647. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 24] [Reference Citation Analysis (0)] |
5. | Ji J, Jin W, Liu SJ, Jiao Z, Li X. Probiotics, prebiotics, and postbiotics in health and disease. MedComm (2020). 2023;4:e420. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 40.0] [Reference Citation Analysis (0)] |
6. | Wang S, Ju D, Zeng X. Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era. Biomedicines. 2024;12. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
7. | Xu YW, Tian J, Song Y, Zhang BC, Wang J. Metabolic syndrome's new therapy: Supplement the gut microbiome. World J Diabetes. 2024;15:793-796. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
8. | Mutalub YB, Abdulwahab M, Mohammed A, Yahkub AM, Al-Mhanna SB, Yusof W, Tang SP, Rasool AHG, Mokhtar SS. Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. Foods. 2022;11. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
9. | Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, Chen XL, Kołat D, Yang K, Hu JK. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023;8:201. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 64] [Reference Citation Analysis (0)] |
10. | Antony MA, Chowdhury A, Edem D, Raj R, Nain P, Joglekar M, Verma V, Kant R. Gut microbiome supplementation as therapy for metabolic syndrome. World J Diabetes. 2023;14:1502-1513. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |